First-in-class small molecule modulators of the IL-6–gp130 axis
Validated Pathway
The IL-6/gp130 signaling axis is a major contributor to chronic inflammation.
Redefining Inflammation
Innata Bio pioneers first-in-class therapies to transform treatment of inflammatory diseases
Differentiated Mechanism
First-in-class small molecules modulate IL-6/gp130 signaling: fine-tuning, not inhibiting.
Unlocking Precision
Modulation enables beneficial signaling downstream of gp130 that inhibition blocks.
Improving Tolerability
Optimizing signaling downstream of the IL-6/gp130 axis reduces inflammation without compromising innate immune functions
Engineered Signaling Beyond Antibody Therapy
“On/Off” Antibody Therapies Oversuppress Immune Responses
When an antibody binds to its target (e.g. IL-6 or IL-6 receptor), it blocks it completely. All downstream signaling is inhibited.
Modulation Allows Beneficial Signaling
Innata's small molecules redefine inflammation by unlocking tunable outputs downstream of gp130, balancing immune signaling.
Broad Therapeutic Potential
We focus on inflammatory diseases with high unmet need: osteoarthritis, idiopathic pulmonary fibrosis and cardiometabolic disorders.
Research in Partnership with
Delete me
Fundamental Advance in Understanding Inflammation
- Featured on the cover of Science Translational Medicine in March 2023
- Dose-dependent reduction in pain and improvement in cartilage regeneration
- Final data will be presented at OARSI World Congress on Osteoarthritis in April 2026
